Search
Lyell Immunopharma Inc
LYELAdd to Watchlist
10.120USD
-0.410-3.89%
Close 09-24 16:00（ET）
236.10MMarket Cap
LossP/E TTM
About Lyell Immunopharma Inc Company
Lyell Immunopharma, Inc. is a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with hematologic malignancies and solid tumors. The Company’s product candidates include LYL314 and LYL273. Its LYL314, which is in Phase I/II clinical development, is a dual-targeting CD19/CD20 CAR T-cell product candidate designed to increase complete response rates and prolong the duration of response as compared to the approved CD19-targeted CAR T-cell therapies and is under evaluation trial for the treatment of patients with relapsed and/or refractory large B-cell lymphoma. The Company has acquired the global rights to LYL273 (formerly GCC19CART), a novel autologous guanylyl cyclase-C (GCC)-targeted CAR T-cell product candidate for the treatment of metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.
Lyell Immunopharma Inc Profile
Ticker SymbolLYEL
Company nameLyell Immunopharma Inc
IPO dateJun 17, 2021
CEOSeely (Lynn)
Number of employees300
Security typeOrdinary Share
Fiscal year-endJun 17
Address201 Haskins Way
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94080
Phone16506950677
Websitehttps://lyell.com/
Ticker SymbolLYEL
IPO dateJun 17, 2021
CEOSeely (Lynn)
Company Executives of Lyell Immunopharma Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Lynn Seely, M.D.
Dr. Lynn Seely, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
27.30K
-36.55%
Dr. Lynn Seely, M.D.
Dr. Lynn Seely, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
27.30K
-36.55%
Dr. Lynn Seely, M.D.
Dr. Lynn Seely, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
27.30K
-36.55%
Dr. Sumant Ramachandra, M.D., Ph.D.
Dr. Sumant Ramachandra, M.D., Ph.D.
Independent Director
Independent Director
10.00K
--
Dr. Sumant Ramachandra, M.D., Ph.D.
Dr. Sumant Ramachandra, M.D., Ph.D.
Independent Director
Independent Director
10.00K
--
Dr. Sumant Ramachandra, M.D., Ph.D.
Dr. Sumant Ramachandra, M.D., Ph.D.
Independent Director
Independent Director
10.00K
--
Dr. Otis W. Brawley, M.D.
Dr. Otis W. Brawley, M.D.
Independent Director
Independent Director
1.78K
--
Dr. Otis W. Brawley, M.D.
Dr. Otis W. Brawley, M.D.
Independent Director
Independent Director
1.78K
--
Dr. Otis W. Brawley, M.D.
Dr. Otis W. Brawley, M.D.
Independent Director
Independent Director
1.78K
--
Dr. Richard D. (Rick) Klausner, M.D.
Dr. Richard D. (Rick) Klausner, M.D.
Chairman of the Board
Chairman of the Board
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Lynn Seely, M.D.
Dr. Lynn Seely, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
27.30K
-36.55%
Dr. Lynn Seely, M.D.
Dr. Lynn Seely, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
27.30K
-36.55%
Dr. Lynn Seely, M.D.
Dr. Lynn Seely, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
27.30K
-36.55%
Dr. Sumant Ramachandra, M.D., Ph.D.
Dr. Sumant Ramachandra, M.D., Ph.D.
Independent Director
Independent Director
10.00K
--
Dr. Sumant Ramachandra, M.D., Ph.D.
Dr. Sumant Ramachandra, M.D., Ph.D.
Independent Director
Independent Director
10.00K
--
Dr. Sumant Ramachandra, M.D., Ph.D.
Dr. Sumant Ramachandra, M.D., Ph.D.
Independent Director
Independent Director
10.00K
--
FAQs
Who are the top five shareholders of Lyell Immunopharma Inc?
The top five shareholders of Lyell Immunopharma Inc are: Dr. Lynn Seely, M.D.
How many institutions hold shares of Lyell Immunopharma Inc (LYEL)?
As of 2026Q1, 256 institutions hold shares of Lyell Immunopharma Inc, with a combined market value of approximately 13.43M, accounting for 57.58% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 1891871.00.